Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Pyxis Oncology, Inc. on June 15, 2026. The meeting was conducted virtually. As of the record date of April 20, 2026, there were 62,855,464 shares of common stock outstanding. A quorum was established with 47,302,035 shares present virtually, in person, or by proxy.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
Two proposals were acted upon by stockholders:
- Proposal One: Election of Class II Directors
- Mr. Thomas Civik: Elected with 27,341,415 votes For, 1,981,857 Withheld, and 17,978,763 Broker Non-Votes.
- Dr. Freda Lewis-Hall, M.D.: Elected with 19,188,755 votes For, 10,134,517 Withheld, and 17,978,763 Broker Non-Votes.
- Mr. Michael A. Metzger: Elected with 26,521,575 votes For, 2,801,697 Withheld, and 17,978,763 Broker Non-Votes.
- All three directors will serve until the 2029 Annual Meeting.
- Proposal Two: Ratification of Independent Auditor
- Stockholders ratified the appointment of Ernst & Young LLP for the fiscal year ending December 31, 2026.
- Votes: 46,203,257 For, 1,076,997 Against, 21,781 Abstain.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the tenure of the newly elected Class II directors (Thomas Civik, Freda Lewis-Hall, Michael A. Metzger) extending to 2029.
- Note the significant number of Broker Non-Votes (17,978,763) on the director election proposals.
- Confirm the ratification of Ernst & Young LLP as the independent auditor for the 2026 fiscal year.
- Review the "Withheld" vote count for Dr. Freda Lewis-Hall, which was notably higher than the other nominees (10,134,517).